Skip to main content
. Author manuscript; available in PMC: 2022 Mar 26.
Published in final edited form as: Lancet Infect Dis. 2018 Aug 17;18(10):1138–1149. doi: 10.1016/S1473-3099(18)30353-0

Figure 4. Annual EC-BSI susceptible and resistant to co-amoxiclav, with and without resistance to gentamicin and ciprofloxacin, according to recent hospital-exposure.

Figure 4

Footnote: IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per year as estimated in 2016.